The oral treatment belzutifan, developed by MSD (known as Merck in the US) and branded as Welireg, has received the green light from the US Food and Drug Administration (FDA) for the treatment of an advanced form of renal cell carcinoma (RCC).
A lead candidate psychedelic drug developed by the US company MindMed has shown the potential to treat generalized anxiety disorder in a phase 2b trial.
Mission Therapeutics, a clinical-stage biotech developing first-in-class therapeutics targeting mitophagy, has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to proceed with a phase 2 trial for its kidney...
A portfolio company created and incubated by Apple Tree Partners (ATP) has raised $52 million in series A funding to enable it to rapidly discover novel small molecule therapeutics.
Patient centric, healthcare data tech company, SEQESTER says it can now deliver real-time and real-world data layering in artificial intelligence (AI) to accelerate drug discovery, thanks to its partnership with Atropos Health.
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
The AIDS and Cancer Specimen (ACSR), a biorepository of specimens collected from persons living with HIV (PLWH) has today (December 12) announced it is using software from Proscia that can provide near real-time access to pathology data to investigators...
Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimer’s Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.
Last-line multiple myeloma patients, who have exhausted other treatment options have been responding to oral drug inobrodib in combination with pomalidomide and dexamethasone (pom and dex).
Science and technology giant, Merck, has launched its first software-as-a-service (SaaS) platform that it says bridges the gap between virtual molecule design and real-world manufacturability.
Millions of US adults suffering from heartburn associated with non-erosive-gastroesophageal-reflux-disease (GERD) could benefit from an impending treatment by Phathom Pharmaceuticals.
Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
A treatment option to reduce the number and intensity of hot flashes and night sweats associated with menopause has been approved by the European Commission (EC).
Today, world-leading generative artificial intelligence (AI) company for life sciences, Yseop, is celebrating its involvement in more than 150 clinical trials with pharma giants around the world.
OSP had a great conversation with Mike Connell, chief operating officer, at Enthought. The discussion centered around aritificial intelligence (AI) which have been the buzzwords in pharma and a number of other industries for at least the last year.
Adults and children in the US with congenital thrombotic thrombocytopenic purpura (cTTP) can now access Adzynma for prophylactic and on-demand treatment.
Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a £1 million investment.
Virtual research organization, ObvioHealth, has just announced the launch of its application programming interface (API) which it says is tailored specifically for digital therapeutics (DTx) clinical trials.
From its origins in ancient military time where the Romans and Greeks used logistics and distribution channels to supply their armies, to today's challenges with the supply chain for pharma ingredients, we enjoyed putting some questions to Univar...
Eli Lilly has invested in its manufacturing capacity once more and has announced plans to build a $2.5 billion high-tech manufacturing site in Germany.
Merck has entered into a $70 million licensing agreement with Abbisko Therapeutics for pimicotinib, which is currently being evaluated in a phase 3 study for the treatment of tenosynovial giant cell tumor (TGCT).
We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the...
A significantly greater improvement in people with depression was achieved after they were given ALT-300, an adjunctive treatment, during a phase 2a study.
The first six companies enter the Deep Tech Lab - Quantum start-up accelerator at BioInnovation Institute (BII) to unlock the potential in quantum science
Using a combination of pre-existing HIV drugs, a medicine for HIV-negative people taken before sex has reduced the chances of getting the virus by 86%.
Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in an early study.
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Sofia Baig is the president of clinical solutions at Precision for Medicine. As a strategic industry leader, she is adept driving organizational change and delivering top- and bottom-line growth.
Professor Deborah Ashby, interim Dean of the Faculty of Medicine, Imperial College, delivered this year’s Sally Hollis Memorial Lecture. OSP enjoyed a discussion with both her and Professor Jennifer Visser-Rogers, vice-president for statistical research...
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.
It is five years this month since a ground-breaking change in UK healthcare history happened – with doctors being able to prescribe cannabis-based medicines for the first time.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
Calliditas Therapeutics AB announced today (November 24) that its partner Everest Medicines has revealed that China's National Medical Products Administration (NMPA) has approved Nefecon.
